Cigarette smoking Not Applicable
Conditions
Interventions
Current interventions as of 05/03/2019:
Three separate populations:
1. Continue to smoke / THP population
Arm A – conventional cigarettes
Sponsors
British American Tobacco (Investments) Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 05/03/2019: 1. Males or non-pregnant, non-lactating females, between 23 and 55 years of age, inclusive. Age verification will be performed by checking government issued identification (e.g. passport or driving licence) during Screening 2. Body mass index (BMI) between 17.6 and 32.0 kg/m2, inclusive, body weight exceeding 50 kg (males) or 40 kg (females) 3. Subjects will be in good health, as judged by the Investigator or their appropriately qualified designee based on: medical history, physical examination, vital signs assessment (blood pressure 200 ng/mL and an exhaled breath CO level = 7 ppm at Screening 11. Subjects in Arm A who continue to smoke will be willing to use factory-manufactured non-mentholated cigarettes and/or roll your own cigarettes. 12. Subjects in Arms B will be willing to use the study product (THP) provided to them during the study 13. Subjects in Arm D will be willing to abstain from smoking and using NGPs Arm E: 14. Subjects will have never smoked (<100 cigarettes in their life and none within 30 days prior to Screening) and will continue to not smoke or use any form of tobacco or nicotine-containing product (including THPs) for the duration of the study. Previous inclusion criteria: 1. Males or non-pregnant, non-lactating females, between 23 and 55 years of age, inclusive 2. Body mass index (BMI) between 17.6 and 32.0 kg/m2, inclusive, body weight exceeding 50 kg (males) or 40 kg (females) 3. Subjects will be in good health, as judged by the Investigator or their appropriately qualified designee based on: medical history, physical examination, vital signs assessment (blood pressure <140 mmHg systolic
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 05/03/2019: 1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e. a condom with spermicide) or to refrain from donating sperm from Visit 1 until the end of the Follow-up Visit 2. Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e. a condom with spermicide) from the time of signing the ICF until the end of the Follow-up Visit 3. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and Visit 1. Any female subject who becomes pregnant during this study will be withdrawn 4. Subjects who have donated: =400 mL of blood within 12 weeks (male) or 16 weeks (female) prior to Visit 1, plasma in the 2 weeks prior to Visit 1, platelets in the 6 weeks prior to Visit 1 5. Subjects who have an acute illness (e.g. upper respiratory tract infection) requiring treatment within 4 weeks prior to Visit 1 (subjects who had viral infections that resolved =2 weeks prior to Visit 1 will be admissible to this study) 6. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the Investigator 7. Subjects who have a positive urine drugs of abuse screen (confirmed by repeat) at Screening or Visit 1 or a positive alcohol breath test (confirmed by repeat) at Screening or Visit 1 8. Subjects who are carriers of the hepatitis B surface antigen (HBsAg), hepatitis C antibody or have a positive result for the test for human immunodeficiency virus (HIV) antibodies 9. Subjects who have used prescription or over-the-counter (OTC) bronchodilator medication (e.g. inhaled or oral ß-adrenergic agonists) to treat a chronic condition within the 12 months prior to Visit 1 10. Subjects who have received any medications or substances (other than tobacco) which interfere with the cyclooxygenase pathway (e.g. anti-inflammatory drugs including aspirin and ibuprofen) within 14 days prior to Visit 1, are known to be strong inducers or inhibitors of cytochrome P450 (CYP) enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to Visit 1 11. Subjects who perform strenuous physical activity (exceeding the subject’s normal activity levels) within 7 days prior to Screening or Visit 1 12. Subjects who are unable to communicate effectively with the Investigator/study staff (i.e. language problem, poor mental development, or impaired cerebral function) 13. Subjects who are unwilling or unable to comply with the study restrictions and requirements 14. Employees and immediate relatives of the tobacco industry and the clinical site 15. Subjects who are still participating in another clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first product use 16. Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (post-bronchodilator FEV1/FVC < 0.7 and FEV1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using 24-hour urine ambulatory collection at visits 1, 2 ,3, 4, 7, 10, 13: 1. Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL) 2. 8-epi-prostaglandin F2a Type III (8-Epi-PGF2a Type III) Physiological measures, measured at visits 1, 2 ,3, 4, 7, 10, 13: 1. Augmentation Index (AIx) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 05/03/2019: Measured from 24-hour urine ambulatory collection at visits 1, 2, 3, 4, 7, 10, 13: 1. Total nicotine equivalents (nicotine, cotinine, 3-hydroxycotinine and their glucuronide conjugates) (TNeq) 2. Total N-nitrosonornicotine (Total NNN) 3. 3-hydroxypropylmercapturic acid (3-HPMA) 4. 3-hydroxy-1-methylpropylmercapturic acid (HMPMA) 5. S-phenylmercapturic acid (S-PMA) 6. Monohydroxybutenyl-mercapturic acid (MHBMA) 7. 2-cyanoethylmercapturic acid (CEMA) 8. 1-hydroxypyrene (1-OHP) 9. 2-hydroxyethylmercapturic acid (HEMA) 10. 11-dehydrothromboxane B2 (11-dTX B2) 11. 4-hydroxy-nonenal + metabolites (4-HNE) 12. Creatinine 13. 4-aminobiphenyl (4-ABP) 14. 2-aminonaphthalene (2-AN) 15. ortho-toluidine (o-Tol) Measured from blood samples: 1. N-(2-cyanoethyl)valine (HB [haemoglobin] adduct; CEVal) measured at visits 1, 2 ,3, 4, 7, 10, 13 2. White blood cell count (WBC count) measured at visits 1, 2 ,3, 4, 7, 10, 13 3. Monocyte chemotactic protein 1/C-C motif chemokine ligand 2 (MCP 1/CCL2) measured at visits 1, 4, 7, 10, 13 4. Soluble intercellular adhesion molecule-1 (s-ICAM1) measured at visits 1, 4, 7, 10, 13 5. Fibrinogen (Fib) measured at visits 1, 4, 7, 10, 13 6. High-sensitivity C-reactive protein (hsCRP) measured at visits 1, 4, 7, 10, 13 7. Homocysteine (HMCys) measured at visits 1, 4, 7, 10, 13 8. Glucose (Gluc) measured at visits 1, 4, 7, 10, 13 9. Plasminogen activator inhibitor-1 (PAI-1) measured at visits 1, 4, 7, 10, 13 10. Tissue plasminogen activator (tPA) measured at visits 1, 4, 7, 1 | — |
Countries
England, Northern Ireland, United Kingdom, Wales
Contacts
Public ContactNathan Gale
Outcome results
None listed